๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis

โœ Scribed by C. Galabert; J.C. Montet; D. Lengrand; A. Lecuire; C. Sotta; C. Figarella; J.P. Chazalette

Book ID
117163624
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
333 KB
Volume
121
Category
Article
ISSN
1097-6833

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Effects of ursodeoxycholic acid in patie
Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy
โœ Dr. Joaquin Palma; Humberto Reyes; Jose Ribalta; Joaquin Iglesias; Manuel C. Gon ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 672 KB

The efficacy and safety of ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy was investigated in an open pilot study. Five patients received 1 gm/day of ursodeoxycholic acid during 20 days and another three patients received two identical periods of treatment separated b

Scintigraphic documentation of an improv
Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease
โœ Carla Colombo; Maria Rita Castellani; William F. Balistreri; Ettore Seregni; Mar ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 851 KB

We have previously documented that ursodeoxycholic acid exerts a beneficial effect on liver function and bile acid metabolism in patients with cystic fi- brosis. We hypothesized that the mechanism of action may be related in part to the choleretic properties of the administered bile acid. We therefo

Effects of ursodeoxycholic acid (UDCA) o
Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis
โœ E. Rolandi; R. Franceschini; A. Cataldi; V. Cicchetti; L. Carati; T. Barreca ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer ๐ŸŒ English โš– 347 KB

The effects of ursodeoxycholic acid (UDCA, 450 mg daily) in patients with histologically proven chronic active hepatitis (CAH) have been evaluated in a randomized, double-blind, placebo-controlled study. Twenty-six patients with serum alanine aminotransferase (ALT) values at least twice the normal u